Record title

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Record identifier

TN_cdi_hal_primary_oai_HAL_hal_03046446v1

https://collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03046446v1

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

About this item

Full title

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2020, Vol.396 (10257), p.1090-1100

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_03046446v1

Language

English

Formats

Publication information

Publisher

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_03046446v1

Permalink

https://collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03046446v1

Other Identifiers

ISSN

E-ISSN

DOI

How to access this item